Thioredoxin reductase inhibitors: a patent review

References

• Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102–6109.
   PubMedGoogle Scholar
• Gromer S, Urig S, Becker K. The thioredoxin system–from science to clinic. Med Res Rev. 2004;24:40–89.
   PubMed Web of Science ®Google Scholar
• Hanschmann EM, Godoy JR, Berndt C, et al. Thioredoxins, glutaredoxins, and peroxiredoxins–molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal. 2013;19:1539–1605.
   PubMed Web of Science ®Google Scholar
• Arner ES. Focus on mammalian thioredoxin reductases–important selenoproteins with versatile functions. Biochim Biophys Acta. 2009;1790:495–526.
   PubMed Web of Science ®Google Scholar
• Sandalova T, Zhong L, Lindqvist Y, et al. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A. 2001;98:9533–9538.
   PubMed Web of Science ®Google Scholar
• Fritz-Wolf K, Urig S, Becker K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J Mol Biol. 2007;370:116–127.
   PubMed Web of Science ®Google Scholar
• Zhong L, Arner ES, Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A. 2000;97:5854–5859.
   PubMed Web of Science ®Google Scholar
• Conrad M, Jakupoglu C, Moreno SG, et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol. 2004;24:9414–9423.
   PubMed Web of Science ®Google Scholar
• Jakupoglu C, Przemeck GK, Schneider M, et al. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol. 2005;25:1980–1988.
   PubMed Web of Science ®Google Scholar
• Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006;16:420–426.
   PubMed Web of Science ®Google Scholar
• Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res. 2009;53:87–103.
   PubMed Web of Science ®Google Scholar
• Benhar M, Shytaj IL, Stamler JS, et al. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 2016;126:1630–1639.
   PubMed Web of Science ®Google Scholar
• Berggren M, Gallegos A, Gasdaska JR, et al. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 1996;16:3459–3466.
   PubMed Web of Science ®Google Scholar
• Shao L, Diccianni MB, Tanaka T, et al. Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res. 2001;61:7333–7338.
   PubMed Web of Science ®Google Scholar
• Lincoln DT, Ali Emadi EM, Tonissen KF, et al. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003;23:2425–2433.
   PubMed Web of Science ®Google Scholar
• Gallegos A, Gasdaska JR, Taylor CW, et al. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res. 1996;56:5765–5770.
   PubMed Web of Science ®Google Scholar
• Yoo MH, Xu XM, Carlson BA, et al. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 2006;281:13005–13008.
   PubMed Web of Science ®Google Scholar
• Hellfritsch J, Kirsch J, Schneider M, et al. Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumor-derived angiogenesis. Antioxid Redox Signal. 2015;22:938–950.
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002;62:5089–5095.
   PubMed Web of Science ®Google Scholar
• Farina AR, Tacconelli A, Cappabianca L, et al. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur J Biochem. 2001;268:405–413.
   PubMedGoogle Scholar
• Maeda R, Tabata C, Tabata R, et al. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal. 2011;15:685–689.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zheng X, Wang X. Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer. Am J Cancer Res. 2015;5:2788–2798.
   PubMed Web of Science ®Google Scholar
• Yamada M, Tomida A, Yoshikawa H, et al. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res. 1996;2:427–432.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Miyoshi Y, Taguchi T, et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res. 2005;11:8425–8430.
   PubMed Web of Science ®Google Scholar
• Javvadi P, Hertan L, Kosoff R, et al. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res. 2010;70:1941–1950.
   PubMed Web of Science ®Google Scholar
• Arner ES, Zhong L, Holmgren A. Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol. 1999;300:226–239.
   PubMed Web of Science ®Google Scholar
• Hill KE, McCollum GW, Burk RF. Determination of thioredoxin reductase activity in rat liver supernatant. Anal Biochem. 1997;253:123–125.
   PubMed Web of Science ®Google Scholar
• Zhang L, Duan D, Liu Y, et al. Highly selective off-on fluorescent probe for imaging thioredoxin reductase in living cells. J Am Chem Soc. 2014;136:226–233.
   PubMed Web of Science ®Google Scholar
• Dai F, Liu GY, Li Y, et al. Insights into the importance for designing curcumin-inspired anticancer agents by a prooxidant strategy: the case of diarylpentanoids. Free Radic Biol Med. 2015;85:127–137.
   PubMed Web of Science ®Google Scholar
• Peng S, Zhang B, Meng X, et al. Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents. J Med Chem. 2015;58:5242–5255.
   PubMed Web of Science ®Google Scholar
• Peng S, Zhang B, Yao J, et al. Dual protection of hydroxytyrosol, an olive oil polyphenol, against oxidative damage in PC12 cells. Food Funct. 2015;6:2091–2100.
   PubMed Web of Science ®Google Scholar
• Zhang B, Duan D, Ge C, et al. Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent. J Med Chem. 2015;58:1795–1805.
   PubMed Web of Science ®Google Scholar
• Engelman R, Ziv T, Arner ES, et al. Inhibitory nitrosylation of mammalian thioredoxin reductase 1: molecular characterization and evidence for its functional role in cellular nitroso-redox imbalance. Free Radic Biol Med. 2016;97:375–385.
   PubMed Web of Science ®Google Scholar
• Duan D, Zhang J, Yao J, et al. targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of hela cells. J Biol Chem. 2016;291:10021–10031.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Duan D, et al. Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells. Biochem Pharmacol. 2016;102:34–44.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma H, Zhang L, et al. A small molecule probe reveals declined mitochondrial thioredoxin reductase activity in a parkinson’s disease model. Chem Commun. 2016;52:2296–2299.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang J, Zhang Z, et al. A fast response and red emission probe for mammalian thioredoxin reductase. Chem Commun. 2016;52:12060–12063.
   PubMed Web of Science ®Google Scholar
• Rigobello MP, Scutari G, Folda A, et al. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol. 2004;67:689–696.
   PubMed Web of Science ®Google Scholar
• Saggioro D, Rigobello MP, Paloschi L, et al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol. 2007;14:1128–1139.
   PubMedGoogle Scholar
• Citta A, Schuh E, Mohr F, et al. Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. Metallomics. 2013;5:1006–1015.
   PubMed Web of Science ®Google Scholar
• Bertrand B, Citta A, Franken IL, et al. Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents. J Biol Inorg Chem. 2015;20:1005–1020.
   PubMed Web of Science ®Google Scholar
• Gandin V, Fernandes AP. metal- and semimetal-containing inhibitors of thioredoxin reductase as anticancer agents. Molecules. 2015;20:12732–12756.
   PubMed Web of Science ®Google Scholar
• Cai W, Zhang L, Song Y, et al. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med. 2012;52:257–265.
   PubMed Web of Science ®Google Scholar
• Bindoli A, Rigobello MP, Scutari G, et al. Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coordin Chem Rev. 2009;253:1692–1707.
   Web of Science ®Google Scholar
• Lowe G. Platinum (II) compounds. WO 0050431.2000.
   Google Scholar
• Davioud-Charvet E, Becker-Brandenburg K, Deborde V, et al. Phosphole derivatives complexed with metals, and pharmaceutical uses thereof. US 2008045465.2008.
   Google Scholar
• Becker-Brandenburg K, Davioud-Charvet E, Deborde V, et al. Phosphole derivatives complexed with metals, and pharmaceutical uses thereof WO 2006024770.2007.
   Google Scholar
• Li M, Shi X, Du L Triazole goldcompound as well as preparation method and application thereof. CN 105001244.2015.
   Google Scholar
• Wang H, Zhang D, Zhao YX Golden phosphorous acetyletic compound, and preparation method and applications thereof. CN 103467516.2013.
   Google Scholar
• Zhang D, Xu Z, Yuan J, et al. Synthesis and molecular recognition studies on small-molecule inhibitors for thioredoxin reductase. J Med Chem. 2014;57:8132–8139.
   PubMed Web of Science ®Google Scholar
• Gao X Peptide-bound gold metal nano-clusters as cancer cell killing agents. US 20140256038.2014.
   Google Scholar
• Che CM Metal complexes of thiourea and their derivatives as metal delivering anti-cancer and anti-inflammatory agents. WO 2011134275.2011.
   Google Scholar
• Che CM Metal complexes of thiourea and derivatives as metal delivering anti-cancer and anti-inflammatory agents. US 8722897;2014.
   Google Scholar
• Che CM, Zou T Binuclear gold(I) diphosphine bis-carbene- and dithiocarbamate-bridged complexes as non-toxic antitumor agents. WO 2014075574.2014.
   Google Scholar
• Che CM, Zou T Method of using binuclear gold (I) compounds for cancer treatment. US 9238659.2016.
   Google Scholar
• Che CM, Zou T Novel gold(III) bis-azolatopyridine complexes containing N-heterocyclic carbene ligands, synthesis, and their. WO 2014075394 2014.
   Google Scholar
• Che CM, Zou T. gold(III) complexes containing N-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection. US 8828984.2014.
   Google Scholar
• Gan FF, Kaminska KK, Yang H, et al. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxid Redox Signal. 2013;19:1149–1165.
   PubMed Web of Science ®Google Scholar
• Cai W, Zhang B, Duan D, et al. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol Appl Pharmacol. 2012;262:341–348.
   PubMed Web of Science ®Google Scholar
• Duan D, Zhang B, Yao J, et al. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. Free Radic Biol Med. 2014;70:182–193.
   PubMed Web of Science ®Google Scholar
• Duan D, Zhang B, Yao J, et al. Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase. Free Radic Biol Med. 2014;69:15–25.
   PubMed Web of Science ®Google Scholar
• Chew EH, Nagle AA, Zhang Y, et al. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med. 2010;48:98–111.
   PubMed Web of Science ®Google Scholar
• Zou P, Xia Y, Ji J, et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. Cancer Lett. 2016;375:114–126.
   PubMed Web of Science ®Google Scholar
• Citta A, Folda A, Bindoli A, et al. Evidence for targeting thioredoxin reductases with ferrocenyl quinone methides. A possible molecular basis for the antiproliferative effect of hydroxyferrocifens on cancer cells. J Med Chem. 2014;57:8849–8859.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yao J, Peng S, et al. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase. Biochim Biophys Acta. 2016. DOI:10.1016/j.bbadis.2016.10.019
   Web of Science ®Google Scholar
• Stevens MFG, Wells G, Westwell AD, et al. 4-aryl quinols and analogs thereof as therapeutic agents. US 7144893.2006.
   Google Scholar
• Stevens MFG, Westwell AD, Poole TD, et al. 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents. WO 2004056361.2004.
   Google Scholar
• Stevens MFG, Westwell AD, Poole TD, et al. 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents. US 7307099.2007.
   Google Scholar
• Stevens MFG, Westwell AD, Wells G, et al. 4-Aryl quinols and analogs thereof as therapeutic agents. US 2004220236.2004.
   Google Scholar
• Stevens MFG, Wells G, Westwell AD 4-Aryl quinols and analogs thereof as therapeutic agents [en] 4-aryl quinols et leurs analogues utilises en tant qu’agents therapeutiques. WO 03004479.2003.
   Google Scholar
• Pallis M, Bradshaw TD, Westwell AD, et al. Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochem Pharmacol. 2003;66:1695–1705.
   PubMed Web of Science ®Google Scholar
• Wells G, Berry JM, Bradshaw TD, et al. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem. 2003;46:532–541.
   PubMed Web of Science ®Google Scholar
• Bradshaw TD, Matthews CS, Cookson J, et al. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res. 2005;65:3911–3919.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Westwell AD, Bradshaw TD, et al. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer. 2005;92:350–358.
   PubMed Web of Science ®Google Scholar
• Ostaszewski R, Klossowski S, Ziuzia I, et al. Novel esters of (acyloxmethy)acrylamide, a pharmaceutical, composition containing them, and their use as inhibitors of the thioredoxin-thioredoxin reductase system. WO 2012050465.2012.
   Google Scholar
• Sasada T, Nakamura H, Ueda S, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med. 1999;27:504–514.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DL, Kuperus M, Dowdeswell M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol. 1998;55:987–994.
   PubMed Web of Science ®Google Scholar
• Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem. 2005;280:25284–25290.
   PubMed Web of Science ®Google Scholar
• Gromer S, Arscott LD, Williams CH Jr., et al. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem. 1998;273:20096–20101.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick LD, Powis G Inhibitors of redox signaling and methods of using same. US 6372772.2002.
   Google Scholar
• Kunkel MW, Kirkpatrick DL, Johnson JI, et al. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des. 1997;12:659–670.
   PubMedGoogle Scholar
• Powis G, Wipf P Palmarumycin based inhibitors of thioredoxin and methods of using same. WO 2007035641.2007.
   Google Scholar
• Lazo JS, Wipf P, Day BW. Syntheses and methods of use of new antimitotic agents. US 6673937.2004.
   Google Scholar
• Powis G, Wipf P Palmarumycin based inhibitors of thioredoxin and methods of using same. US 8124651.2012.
   Google Scholar
• Powis G, Wipf P, Lynch SM, et al. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther. 2006;5:630–636.
   PubMed Web of Science ®Google Scholar
• Fidler JM, Musser JH Identification and screening of triptolide target molecules. US 8617906.2013.
   Google Scholar
• Kumar S, Bjornstedt M, Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem. 1992;207:435–439.
   PubMedGoogle Scholar
• Engman L, Kandra T, Gallegos A, et al. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des. 2000;15:323–330.
   PubMedGoogle Scholar
• Kirckpatrick LD Asymmetric disulfides and methods of using same. US 20030176512.2003.
   Google Scholar
• Kirckpatrick LD, Asymmetric PG Disulfides and methods of using same. US 20040116496.2004.
   Google Scholar
• Kirkpatrick LD Asymmetric disulfides and methods of using same. US 6552060 2003.
   Google Scholar
• Ramanathan RK, Abbruzzese J, Dragovich T, et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol. 2011;67:503–509.
   PubMed Web of Science ®Google Scholar
• Zeng H Benzisoselenazolone difluorocytidine compound as well as preparation method and application thereof. CN 101921303.2010.
   Google Scholar
• Zeng H Benzisoselenazolone difluorocytidine compound as well as preparation method and application thereof. CN 101781283.2010.
   Google Scholar
• Zeng H Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use. US 20050014801.2005.
   Google Scholar
• Hausheer FH Compositions and methods of use of compounds to increase cancer patient survival time. US 20090232827.2009.
   Google Scholar
• Bible KC, Isham CR, Xu R, et al. Methods and compositions for treating cancer. US 20090264421.2009.
   Google Scholar
• Eastwood EL, Schaus SE Thioredoxin and thioredoxin reductase inhibitors. WO 2007103273.2007.
   Google Scholar
• Rigas B Methods of treating proliferative disorders. WO 2014172315.2014.
   Google Scholar
• Huang L, Wong CC, Mackenzie GG, et al. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer. 2014;14:141.
   PubMed Web of Science ®Google Scholar
• Todd A, Rj A, Small DAP, et al. Preparation of bis-sulfonamides as thioredoxin reductase inhibitors. WO 2014096864.2014.
   Google Scholar
• Witte AB, Anestal K, Jerremalm E, et al. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med. 2005;39:696–703.
   PubMed Web of Science ®Google Scholar
• Reich HJ, Hondal RJ. Why nature chose selenium. ACS Chem Biol. 2016;11:821–841.
   PubMed Web of Science ®Google Scholar
• Reeves MA, Hoffmann PR. The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci. 2009;66:2457–2478.
   PubMed Web of Science ®Google Scholar
• Nero TL, Morton CJ, Holien JK, et al. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer. 2014;14:248–262.
   PubMed Web of Science ®Google Scholar
• Rees DC, Congreve M, Murray CW, et al. Fragment-based lead discovery. Nat Rev Drug Discov. 2004;3:660–672.
   PubMed Web of Science ®Google Scholar
• Guo W, Wisniewski JA, Ji H. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett. 2014;24:2546–2554.
   PubMed Web of Science ®Google Scholar
• Fritz-Wolf K, Kehr S, Stumpf M, et al. Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat Commun. 2011;2:383.
   PubMed Web of Science ®Google Scholar
• Fritz-Wolf K, Jortzik E, Stumpf M, et al. Crystal structure of the plasmodium falciparum thioredoxin reductase-thioredoxin complex. J Mol Biol. 2013;425:3446–3460.
   PubMed Web of Science ®Google Scholar